TNDM Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.…
Industry Peers
Medical DevicesKey Statistics
About Tandem Diabetes Care (NASDAQ: TNDM)
›
Tandem Diabetes Care (NASDAQ: TNDM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2,500 employees.
The shares were at 16.80 USD on 19 November 2026, up 14.5% over 52 weeks. Its 52-week range is 12.26 USD to 29.65 USD: the price is 43.3% below the high and 37.0% above the low.
Its market capitalisation is 1.17B USD.
Tandem Diabetes Care reports return on equity of -131.9%, an operating margin of -2.4% and revenue up 13.8% year over year.
Its debt exceeds its cash by 293.46M USD, a debt-to-equity ratio of 2.86. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 21 analysts cover the stock, with an average rating of Buy; their mean price target of 27.10 USD is 61.3% above the current price. The next earnings report is expected on 18 February 2027.